Agios Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (2007)
Status: Acquired by Servier (2020)

Organization Overview

First Clinical Trial
2013
NCT01915498
First Marketed Drug
2018
ivosidenib (tibsovo)
First NDA Approval
2018
ivosidenib (tibsovo)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Agios Pharmaceuticals | Agios Pharmaceuticals, Inc. | AGIOS PHARMS INC

Indications

Approved Indications


 

Leukemia, Myeloid, Acute

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Hemolytic (Phase 3)

Anemia, Hemolytic, Congenital Nonspherocytic (Phase 3)

Anemia, Sickle Cell (Phase 1)

Cholangiocarcinoma (Phase 3)

Chondrosarcoma (Phase 2)

Glioma (Phase 3)

Hematologic Diseases (Phase 1)

Hematologic Neoplasms (Phase 2)

Immunoblastic Lymphadenopathy (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Preleukemia (Phase 1)

Pyruvate Metabolism, Inborn Errors (Phase 3)

Syndrome (Phase 1)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 54
  • # of Trial APIs: 25